Reviva Pharmaceuticals Holdings (RVPH) Total Non-Current Liabilities (2021 - 2025)

Reviva Pharmaceuticals Holdings has reported Total Non-Current Liabilities for 5 years, with the latest figure at $7.3 million in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 50.17% year-over-year to $7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (down 50.17% YoY) and the FY2025 annual result came in at $7.3 million, down 50.17% from the prior year.
• Total Non-Current Liabilities eased to $7.3 million in Q4 2025 per RVPH's latest filing, from $9.7 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $17.5 million in Q3 2024 and troughed at $973700.0 in Q3 2021.
• A 5-year average of $9.8 million and a median of $10.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities jumped 555.17% in 2022, then plunged 50.17% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $973700.0 in 2021, then surged by 923.11% to $10.0 million in 2022, then soared by 72.41% to $17.2 million in 2023, then declined by 14.98% to $14.6 million in 2024, then slumped by 50.17% to $7.3 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $7.3 million, $9.7 million, and $12.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.